清晨好,您是今天最早来到科研通的研友!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您科研之路漫漫前行!

Apatinib as second-line or later therapy in patients with advanced hepatocellular carcinoma (AHELP): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

阿帕蒂尼 医学 内科学 肝细胞癌 临床终点 安慰剂 临床试验 肿瘤科 不利影响 舒尼替尼 胃肠病学 外科 索拉非尼 化疗 癌症 病理 替代医学
作者
Shukui Qin,Li Qiu,Shanzhi Gu,Xiaohong Chen,Li-zhu Lin,Zishu Wang,Aibing Xu,Xi Chen,Cuncai Zhou,Zhenggang Ren,Lin Yang,Li Xu,Yuxian Bai,Lei Chen,Jun Li,Hongming Pan,Bangwei Cao,Weijia Fang,Wei Wu,Ge Wang,Ying Cheng,Zhuang Yu,Xu Zhu,Da Jiang,Yinying Lu,Huaming Wang,Jianming Xu,Li Bai,Yunpeng Liu,Hailan Lin,Changping Wu,Yang Zhang,Ping Yan,Chunlei Jin,Jianjun Zou
出处
期刊:The Lancet Gastroenterology & Hepatology [Elsevier]
卷期号:6 (7): 559-568 被引量:161
标识
DOI:10.1016/s2468-1253(21)00109-6
摘要

Background Inhibition of vascular endothelial growth factor receptor (VEGFR) has shown antitumour activity in advanced hepatocellular carcinoma, but few studies of VEGFR inhibitors have been done in populations with a high prevalence of hepatitis B virus infection. The aim of this study was to evaluate the efficacy and safety of apatinib in patients with pretreated advanced hepatocellular carcinoma. Methods AHELP was a randomised, double-blind, placebo-controlled, phase 3 trial done at 31 hospitals in China, in patients (aged ≥18 years) with advanced hepatocellular carcinoma who had previously been refractory or intolerant to at least one line of systemic chemotherapy or targeted therapy. Patients were randomly assigned (2:1) to receive apatinib 750 mg or placebo orally once daily in 28-day treatment cycles. Group allocation was done with a central randomisation system, with a block size of six, and was stratified by Eastern Cooperative Oncology Group performance status, previous sorafenib treatment, and presence of vascular invasion or extrahepatic metastasis. The primary endpoint was overall survival, which was defined as time from randomisation to death from any cause, and was analysed in patients who were randomly assigned and received at least one dose of the study drug. Safety analyses were done in patients who received at least one dose of the study treatment and had post-dose safety assessments. This trial is registered with ClinicalTrials.gov, NCT02329860. Findings Between April 1, 2014, and May 3, 2017, 400 eligible patients were randomly assigned to receive apatinib (n=267) or placebo (n=133). Seven patients (six in the apatinib group and one in the placebo group) did not receive study treatment and were excluded from efficacy analyses. Overall survival was significantly improved in the apatinib group compared with the placebo group (median 8·7 months [95% CI 7·5‒9·8] vs 6·8 months [5·7‒9·1]; hazard ratio 0·785 [95% CI 0·617‒0·998], p=0·048). 387 patients (257 in the apatinib group and 130 in the placebo group) had a safety assessment after study treatment and were included in safety analyses. The most common treatment-related adverse events of grade 3 or 4 were hypertension (71 [28%] patients in the apatinib group vs three [2%] in the placebo group), hand–foot syndrome (46 [18%] vs none), and decreased platelet count (34 [13%] vs one [1%]). 24 (9%) patients in the apatinib group and 13 (10%) in the placebo group died due to adverse events, but none of these deaths were deemed to be related to treatment by investigators. Interpretation Apatinib significantly improved overall survival in patients with pretreated advanced hepatocellular carcinoma compared with placebo, with a manageable safety profile. Funding Jiangsu Hengrui Medicine.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
gmc完成签到 ,获得积分10
29秒前
谷子完成签到 ,获得积分10
30秒前
数乱了梨花完成签到 ,获得积分10
38秒前
寒战完成签到 ,获得积分10
46秒前
沐浠完成签到 ,获得积分10
58秒前
salty完成签到 ,获得积分10
1分钟前
桐桐应助123采纳,获得10
1分钟前
Shandongdaxiu完成签到 ,获得积分10
1分钟前
HCKACECE完成签到 ,获得积分10
1分钟前
Vicky完成签到 ,获得积分10
1分钟前
1分钟前
丰富的绮山完成签到,获得积分10
1分钟前
烟花应助科研通管家采纳,获得30
1分钟前
Akim应助科研通管家采纳,获得30
1分钟前
123发布了新的文献求助10
1分钟前
段采萱完成签到 ,获得积分10
1分钟前
Ava应助123采纳,获得30
1分钟前
leng完成签到 ,获得积分10
1分钟前
dragonhmw完成签到 ,获得积分10
1分钟前
烟花应助依居采纳,获得10
2分钟前
玉一一完成签到 ,获得积分10
2分钟前
哈拉斯完成签到,获得积分10
2分钟前
2分钟前
依居发布了新的文献求助10
2分钟前
蓝胖胖蓝完成签到,获得积分10
2分钟前
2分钟前
稀松完成签到,获得积分10
2分钟前
2分钟前
陌子完成签到 ,获得积分10
2分钟前
zjq完成签到 ,获得积分10
2分钟前
3分钟前
飞云完成签到 ,获得积分10
3分钟前
铁妹儿完成签到 ,获得积分10
3分钟前
SHD完成签到 ,获得积分10
3分钟前
煜琪完成签到 ,获得积分10
3分钟前
高贵逍遥完成签到 ,获得积分10
4分钟前
wyh295352318完成签到 ,获得积分10
4分钟前
jie完成签到 ,获得积分10
4分钟前
さくま完成签到,获得积分10
4分钟前
啥时候能早睡完成签到 ,获得积分10
4分钟前
高分求助中
좌파는 어떻게 좌파가 됐나:한국 급진노동운동의 형성과 궤적 2500
Sustainability in Tides Chemistry 1500
TM 5-855-1(Fundamentals of protective design for conventional weapons) 1000
Cognitive linguistics critical concepts in linguistics 800
Threaded Harmony: A Sustainable Approach to Fashion 799
Livre et militantisme : La Cité éditeur 1958-1967 500
氟盐冷却高温堆非能动余热排出性能及安全分析研究 500
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3052644
求助须知:如何正确求助?哪些是违规求助? 2709863
关于积分的说明 7418252
捐赠科研通 2354395
什么是DOI,文献DOI怎么找? 1246007
科研通“疑难数据库(出版商)”最低求助积分说明 605951
版权声明 595921